#Amgen’s Dark Blue deal (up to $840m) is less about one preclinical asset and more about a trend: pharma is paying to remove proteins, not just block them. Feature: https://biotech.industryexaminer.com/amgen-dark-blue-protein-degrader-aml/ #Hematology #AML #Oncology #Biotech #Pharma #DrugDevelopment #ProteinDegradation #TechNews




